GLP-1 Weight Loss Drugs: New Combo Therapy Boosts Results

Recent surveys indicate that approximately 12% of adults in the United States are currently using GLP-1 medications, such as Wegovy or Zepbound, for weight loss or to manage chronic conditions. These medications are generally effective, with most users experiencing a 5% to 15% reduction in body weight over a year.

However, some individuals, potentially up to 20%, do not respond well to GLP-1 treatments alone. Emerging research suggests that a person's genetic makeup may influence their response to these drugs. This has led to the exploration of alternative and complementary therapies.

A recent review highlights the potential benefits of combining GLP-1s with medications like Contrave, which contains naltrexone and bupropion. Contrave works by influencing dopamine pathways in the brain to reduce food cravings and increase feelings of pleasure from food.

Experts propose that this combination therapy makes mechanistic sense. GLP-1s primarily promote satiety and decrease hunger, while Contrave targets the hedonic or pleasure-seeking aspects of eating. This dual action could significantly benefit patients struggling with binge eating, impulsive eating, or persistent food cravings, particularly those who have not achieved at least 5% weight loss with GLP-1s alone.

The consensus among healthcare professionals is that obesity treatment requires a personalized, multi-pronged approach. Combining GLP-1s with medications like Contrave offers a tailored strategy for patients who exhibit a sub-optimal response to GLP-1s, aiming to achieve more meaningful health benefits and weight loss outcomes.